Intracranial germ cell tumours (IGCTs) are a group of rare heterogeneous brain tumours that are clinically and histologically similar to the more common gonadal GCTs. IGCTs show great variation in their geographical and gender distribution, histological composition and treatment outcomes. The incidence of IGCTs is historically fiveto eightfold greater in Japan and other East Asian countries than in Western countries 1 , with peak incidence near the time of puberty 2 . About half of the tumours are located in the pineal region. The maleto-female incidence ratio is approximately 3-4:1 overall, but is even higher for tumours located in the pineal region 3 . Owing to the scarcity of tumour specimens available for research, little is currently known about this rare disease. Here we report the analysis of 62 cases by next-generation sequencing, single nucleotide polymorphism array and expression array. We find the KIT/RAS signalling pathway frequently mutated in more than 50% of IGCTs, including novel recurrent somatic mutations in KIT, its downstream mediators KRAS and NRAS, and its negative regulator CBL. Novel somatic alterations in the AKT/mTOR pathway included copy number gains of the AKT1 locus at 14q32.33 in 19% of patients, with corresponding upregulation of AKT1 expression. We identified loss-of-function mutations in BCORL1, a transcriptional co-repressor and tumour suppressor. We report significant enrichment of novel and rare germline variants in JMJD1C, which codes for a histone demethylase and is a coactivator of the androgen receptor, among Japanese IGCT patients. This study establishes a molecular foundation for understanding the biology of IGCTs and suggests potentially promising therapeutic strategies focusing on the inhibition of KIT/RAS activation and the AKT1/mTOR pathway.
IGCTs are divided into two main groups, pure germinoma and nongerminomatous germ cell tumours (NGGCTs). Germinoma is the most common subtype 1 , accounting for over two thirds of all IGCTs 1, 4 . NGGCTs include teratoma, embryonal carcinoma, yolk sac tumour and choriocarcinoma. About 10% of germinomas and most NGGCTs remain refractory to multimodality therapy 4 . The biology of these tumours is currently largely unknown, except for gain-of-function mutations of KIT reported in ,25% of pure germinomas 5, 6 and a few chromosomal abnormalities revealed by comparative genomic hybridization (CGH) [7] [8] [9] . Through an international multicentre collaboration, we have conducted an in-depth analysis of the genetic abnormalities of IGCTs. For the discovery study, whole-exome sequencing of 28 cases yielded an average of 1393 coverage with 95.4% of targeted bases covered by $ 203 (Extended Data Fig. 1 ). We validated a mean of six non-silent mutations per sample (Supplementary Table 1 ), corresponding to approximately 0.50 non-silent mutations per megabase (Mb, Extended Data Fig. 2a, b) . Although there was no significant difference in average mutation rate between pure germinomas and NGGCTs, the mutation rates varied markedly among NGGCTs (Extended Data Fig. 2c ). For the validation study, we performed targeted deep sequencing, with an average depth of coverage of about 1,0003, for an additional 34 IGCT cases using a custom-designed AmpliSeq array (Methods). The mutations identified are listed in Supplementary Table 2 .
The recurrent genetic alterations and clinical data are summarized in Figs 1 and 2. Except for KIT, none of these genes were previously linked to IGCTs. Overall, 53% of the tumours harboured somatic mutations in at least one of the genes involved in KIT/RAS or AKT/mTOR pathways (Fig. 3a, b) . 93% of somatic mutations identified in these pathways were predicted to be deleterious (Supplementary Table 3) .
Oncogenic KIT mutations are common in testicular seminomas 10 and gastrointestinal stromal tumours (GISTs) 11 , resulting in ligandindependent kinase activation 12 . KIT was mutated in 16 IGCT tumours (Fig. 2a) , but not in any NGGCT cases. Mutations in KIT were clustered primarily in exon 17, followed by exon 11 in a pattern similar to that of testicular seminomas 10 , but quite different from GISTs 11 in which mutations cluster in exon 11, followed by the extracellular domain (Fig. 2a) . KIT was overexpressed in the majority of pure germinomas (Extended Data Fig. 3 ), but rarely in NGGCTs. So far, eight tyrosine kinase inhibitors (TKIs) targeting KIT have been approved (Supplementary Table 4 ). Since the long-term side effects of radiation are well recognized, the application of TKIs could potentially benefit IGCT patients through dose reduction or elimination of radiation therapy.
KRAS or NRAS were mutated in 19% of IGCT cases (Extended Data  Fig. 4a ). The KRAS/NRAS and KIT mutations were mutually exclusive genetic events in IGCTs (Fig. 3a, Extended Data Fig. 4b , P 5 0.018). So far, no approved targeted therapies are available for cancers with KRAS mutations. A recent preclinical study of the MEK inhibitor, selumetinib, indicated great efficacy against KRAS-mutated non-small-cell lung cancer cells 13 . Another study showed effectiveness of ERK inhibitors in MEK inhibitor-resistant cells 14 . CBL, encoding a RING finger ubiquitin E3 ligase, was the third most frequently mutated gene in IGCTs (Fig. 2b) . The protein CBL has been shown to function as a negative regulator of receptor protein tyrosine kinases (RPTKs), including KIT, by targeting activated receptors for polyubiquitination and subsequent degradation 15 . CBL mutation is associated with KIT overexpression, aberrant expression of phosphorylated STAT5, and poor prognosis in myeloid malignancies 16 . In this study, three somatic mutations were identified in the RING finger domain, which might abolish CBL-directed polyubiquitination and downregulation of RPTKs 15 , and two recurrent mutations were found in the small linker domain, which are supposed to be oncogenic 15 (Fig. 2b) . KIT was overexpressed in tumour G23 that was wild type for KIT but had a somatic mutation in CBL (Extended Data Fig. 3 ), consistent with its role as a negative regulator of KIT. A recent report showed that dasatinib is the most effective TKI against myeloid leukaemia cell lines that harbour homozygous CBL mutations 17 , and therefore might be an effective agent for the treatment of CBL-mutated IGCTs. We further analysed the copy number status of CBL and found that 13 out of 28 cases had either clonal or subclonal 11q loss of heterozygosity (LOH) spanning the CBL locus (Supplementary Table 5 and Extended Data Fig. 5a ). Tumours G4 and G11 with CBL somatic mutation lost the wild-type allele through clonal and subclonal 11qLOH, respectively (Extended Data Fig. 5b) , further reinforcing the notion that CBL might have an important role in the pathogenesis of IGCTs.
We observed focal amplification of 14q32.33 in five tumours (18%) in the discovery set (Extended Data Fig. 6a ). The amplified region included 2 Mb spanning the AKT1 locus. Among 34 genes within this region, AKT1 was the only known oncogene. We validated AKT1 copy number gains by quantitative PCR for all five cases and seven additional cases in the validation set. Copy number gains at 14q32.33 were associated with elevated messenger RNA expression of AKT1 (Fig. 3c ), but not for other genes in this region (Supplementary Table 6 and Extended Data Fig. 6b ). We also observed strong cytoplasmic and nuclear immunostaining of AKT1 in cases with focal AKT1 copy number gains (Fig. 3d) .
In this study, 75% cases with AKT1 copy number gains were identified in tumours with wild-type KIT, KRAS and NRAS (Fig. 3a) , indicating an important role of AKT/mTOR pathway in IGCTs. The serinethreonine protein kinase AKT is a key intermediate of signalling pathways that regulate cellular processes. AKT activation by mutation is frequently seen in human cancers, but overexpression is rarely reported. However, high-level AKT1 expression was reported in non-small-cell lung cancer, where it was correlated with poor response to cisplatin 18 . Use of AKT1 inhibitors might also be a promising strategy for treating IGCT patients with AKT1 overexpression.
Finally, we identified recurrent somatic mutations in BCORL1, MTOR, TP53, SPTA1, KDM2A and LAMA4 (Fig. 1) . BCORL1, a transcriptional co-repressor located on the X-chromosome (Xq25-q26.1), was thought to be a tumour suppressor gene in acute myelogenous leukaemia 19 . Functional studies have shown that BCORL1 can interact with class II histone deacetylases, the CtBP co-repressor, through the CtBP binding motif-PLDLS and affect the repression of E-cadherin 20 . In this study, BCORL1 was mutated in six male patients (Fig. 2b) . Interestingly, in five of them, mutations were out-of-frame insertions/deletions, potentially resulting in a truncated protein lacking the conserved LXXLL motif, which mediates the hormone-induced interaction between nuclear receptor and co-activators 21 . Given the low mutation rate and early onset of this disease, we sought to identify potential IGCT-predisposing germline mutations. Therefore we screened germline sequence data for genes enriched in novel functional variants in the IGCT discovery cohort compared to control Discovery study (n = 28) Validation study (n = 34) G1  G2  G3  G4  G5  G6  G7  G8  G9  G10  G 11  G12  M1  M2  M3  M8  M4  NG 11  NG1  NG5  NG7  NG2  NG3  NG6  NG8  NG9  NG10  NG12  G13  G14  G15  G16  G17  G18  G19  G20  G21  G22  G23  G24  G25  G26  G27  G28  G29  M5  M6  M7  NG16  NG13  NG19  NG14  NG22  NG15  NG25  NG24  NG17  NG18  NG20  NG21  NG23  NG26   Histology  Y  Y  Y  M  M  I  I  I  I  I  Y  Y  T  T  M  M  I  I  I  I  I  I  Age  Gender  Location  Collection time Ploidy Clonality showed strong and diffuse cytoplasmic and nuclear staining, whereas cases G4, NG2 and NG13 showed strong but focal cytoplasmic and nuclear staining.
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populations (Extended Data Fig. 7 and Supplementary Table 7) . The top four genes most enriched in functional germline variants were CDK5RAP2, JMJD1C, USP35 and PCDH15. Of these, JMJD1C functions as a chromatin modifier gene, and was the only one with a reported role in normal germinal tissue development in both human 22 and mouse models 23 . A recent report showed that it is required in the development and maintenance of germ cells in mice 24 . Thus we included this gene for mutation screening in the validation cohort. In the combined cohorts of 62 cases, we identified novel and rare germline variants in JMJD1C in 10 patients, including a rare dinucleotide polymorphism (AA to GC, S880P) in three genetically unrelated individuals ( Fig. 2b and Supplementary Table 8 ). Among the 10 patients, 9 carriers were from Japan and 1 was from Hong-Kong. JMJD1C germline variants were significantly enriched in the Japanese populations in control cohorts and further enriched (about fivefold) in Japanese IGCT patients (Fig. 4) . The odds ratio is 4.8, indicating a strong association between JMJD1C variants and the risk of developing IGCT. The rare variant association tests 25, 26 also revealed significant association of JMJD1C genotype with this disease (Supplementary Table 9 ). Like BCORL1, there are two conserved LXXLL nuclear-receptor-interacting motifs at the carboxy-terminus of JMJD1C, which mediate the interaction with nuclear receptors. Indeed, JMJD1C is known to interact with the thyroid hormone receptor in the thyroid 27 and was reported to interact with the androgen receptor (AR) in humans 28 . Expression microarrays revealed high JMJD1C and AR expression levels in all 37 ICGT patients tested (Extended Data Fig. 8) .
DNA copy-number and clonality analysis (Methods) of IGCT tumours using single nucleotide polymorphism array data revealed a heterogeneous and complex tumour genome. Nearly half of the tumours were tetraploid and 71% of the analysed cases showed subclonal structure (Extended Data Figs 9 and 10). We observed almost exclusively chromosomal arm-level gains and losses. Chromosome X, 21q, 12p, 1q and 14q were frequently amplified, whereas 11q, 10q, 17p and 13q were frequently deleted. Only copy number gains of X, 12p and loss of 13q have been described previously 29 . Over 90% of the pure germinomas exhibited chromosomal imbalance and acquired uniparental disomy of multiple chromosomes, whereas 40% of the NGGCTs were chromosomally stable. The preponderance of arm-level and chromosomelevel imbalance suggests the possibility that aberrant meiotic division may have a role in the pathogenesis of pure germinomas.
Although pure germinomas respond well to surgery and radiotherapy, the long-term quality of life for about a third of postoperative patients is severely impaired owing to radiotherapy-associated complications.
In addition, nearly 10% of patients develop recurrence even after multimodality therapy 1, 4 . Except for mature teratomas, most NGGCTs remain refractory to available treatments and have a rather poor prognosis 1, 4 . In this study we identified novel and frequent somatic alterations in the KIT/RAS and AKT/mTOR signalling pathways and suggested potentially promising targets for the development of novel therapeutic strategies focusing on inhibition of these pathways. Although fewer therapeutic targets were found in NGGCTs, frequent AKT1 amplification and recurrent mTOR mutations may open the door to possible use of AKT1/mTOR inhibitors. It is intriguing that both histone-modifying genes discovered in this study are implicated in the interaction with nuclear receptor proteins. It suggests the possibility that JMJD1C and BCORL1 might be associated with the male preponderance and age of peak incidence of IGCTs through interaction with AR triggered by elevated levels of androgen hormones at puberty. Further functional studies using mouse models are needed to elucidate the possible role of JMJD1C in the pathogenesis of this disease. This study comprehensively described the genomic heterogeneity and complexity underlying IGCTs and provides a molecular foundation for understanding of the genetic alterations in IGCT.
METHODS SUMMARY
Genomic DNA was extracted following the manufacturer's protocols. Whole-exome sequencing was carried out with NimbleGen in-solution reagents (VCRome2.1, NimbleGen). The target region is 43 Mb. Enriched libraries were sequenced on an Illumina HiSeq2000 platform (Illumina). Whole-exome sequencing data processing and analysis were performed using the standard pipelines (Methods) established at the Human Genome Sequencing Center (HGSC), Baylor College of Medicine. Mutation validation was performed using the Ion Torrent Personal Genome Machine (PGM, Life Technologies). The average coverage was 2,5333 and 1,9233 for tumour and their matched blood pools, respectively. The validation rates were 93% and 89% for somatic substitutions and indels, respectively. A subset of germline variants was validated using Sanger sequencing. For prevalence screening, 23 genes were selected based on the discovery study results (Methods) and an AmpliSeq custom array was designed (Supplementary Table 10 ). The AmpliSeq libraries were constructed from 20 ng DNA (10 ng for each reaction pool) and deep sequencing was performed using Ion Torrent PGM platform. Ion Torrent sequencing data was analysed using Torrent Suite Software v3.0. The average coverage was 8913. DNA copy number analyses were performed using Illumina HumanOmni2.5-8 BeadChip Kit. Single nucleotide polymorphism calls were made using Illumina GenomeStudio Version 2011.1 software. The allele-specific copy number, ploidy and purity were analysed by Genome Alteration Print (GAP) 30 . The focal DNA copy number changes and the clonality analysis were performed using in-house algorithms. Focal AKT1 amplification was validated by quantitative PCR.Immunostaining was carried out with AKT1-specifc goat antibody D-17 (sc-7126, Santa-Cruz Biotechnology) at 1:75 dilution. A complete description of the materials and methods is provided in Methods.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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Patients. The collection of samples was performed at multiple medical institutes in US, Japan and Hong Kong including Texas Children's Hospital (USA, n 5 5), Saitama Medical University Hospital (Japan, n 5 28), Kumamoto University Hospital (Japan, n 5 9), Nagoya University Hospital (Japan, n 5 11), Hokkaido University Hospital (Japan, n 5 2), and Prince of Wales Hospital (Hong Kong, n 5 7). Sample collection was approved by the local Institutional Review Board or institutional ethics committee. Written consent was obtained from all patients in accordance with the Declaration of Helsinki. All tumour samples were given the histological diagnosis by the neuropathologists in the local hospitals according to World Health Organization criteria. In the discovery cohort, 23 out of 28 tumours were obtained before any adjuvant therapy, and 5 (G6, NG3, NG9, NG11 and NG12) tumours were obtained from residual tissue after or during first-line chemotherapy. All tumour specimens were obtained before radiation therapy except M8 which was a recurrent tumour 6 years after radiation therapy. In the validation cohort, 26 out of 34 tumours were obtained before any treatment, and 7 tumours (NG15, NG17, NG18, NG22, NG24, NG25 and NG26) were obtained after or during first-line chemotherapy, and one tumour (G25) was obtained at recurrence after radiation therapy. Of the 62 cases, 29 were diagnosed as pure germinoma, 25 were diagnosed as NGGCT, and 8 were mixed GCTs with germinoma component. DNA extraction. In the discovery series, all analysed tumour DNA was extracted from fresh frozen tissue using QIAamp DNA mini kit (QIAGEN), and peripheral blood DNAs were isolated using Wizard Genomic DNA purification kit (Promega). In the validation series, some cases of tumour DNA were extracted from formalinfixed paraffin-embedded (FFPE) materials using Recover All Total Nucleic Acid Isolation Kit (Life Technologies) following the manufacturer's protocol. Illumina library construction. Illumina libraries were constructed according to the manufacturer's protocol with modifications as described in HGSC website (https://hgsc.bcm.edu/sites/default/files/documents/Illumina_Barcoded_Paired-End_ Capture_Library_Preparation.pdf). Libraries were prepared using Beckman robotic workstations (Biomek NXp and FXp models. Briefly, 1 mg of genomic DNA in 100 ml volume was sheared into fragments of approximately 300-400 base pairs in a Covaris plate with E210 system (Covaris, Inc. Woburn, MA) followed by endrepair, A-tailing and ligation of the Illumina multiplexing PE adaptors. Pre-capture Ligation Mediated-PCR (LM-PCR) was performed for 7 cycles of amplification using the 2X SOLiD Library High Fidelity Amplification Mix (a custom product manufactured by Invitrogen). Universal primer IMUX-P1.0 and a pre-capture barcoded primer IBC were used in the PCR amplification. In total, a set of 12 such barcoded primers were used on these samples. Purification was performed with Agencourt AMPure XP beads after enzymatic reactions. Following the final XP bead purification, quantification and size distribution of the pre-capture LM-PCR product was determined using the LabChip GX electrophoresis system (PerkinElmer). Exome capture. Four pre-capture libraries were pooled together (approximately 250 ng per sample, 1 mg per pool) and hybridized in solution to the HGSC VCRome 2.1 design1 (42 Mb, NimbleGen) according to the manufacturer's protocol NimbleGen SeqCap EZ Exome Library SR User's Guide (Version 2.2) with minor revisions. Human Cot-1 DNA (Agilent Technologies) and full-length Illumina adaptor-specific blocking oligonucleotides were added into the hybridization to block repetitive genomic sequences and the adaptor sequences. Post-capture LM-PCR amplification was performed using the 2X SOLiD Library High Fidelity Amplification Mix with 14 cycles of amplification. After the final AMPure XP bead purification, quantity and size of the capture library was analysed using the Agilent Bioanalyzer 2100 DNA Chip 7500. The efficiency of the capture was evaluated by performing a qPCRbased quality check on the four standard NimbleGen internal controls. Successful enrichment of the capture libraries was estimated to range from a 6 to 9 of DC t value over the non-enriched samples. Aliquots of enriched libraries (10 nM) were submitted for sequencing. Illumina sequencing. Library templates were prepared for sequencing using Illumina's cBot cluster generation system with TruSeq PE Cluster Generation Kits (Part no. PE-401-3001). Briefly, these libraries were denatured with sodium hydroxide and diluted to 3-6 pM in hybridization buffer in order to achieve a load density of ,800,000 clusters per mm 2 . Each library pool was loaded in a single lane of a HiSeq flow cell, and each lane was spiked with 1% PhiX control library (Illumina) for run quality control. The sample libraries then underwent bridge amplification to form clonal clusters, followed by hybridization with the sequencing primer. Sequencing runs were performed in paired-end mode using the Illumina HiSeq 2000 platform. Using the TruSeq SBS Kits (Part no. FC-401-3001), sequencing-by-synthesis reactions were extended for 101 cycles from each end, with an additional 7 cycles for the index read. Real Time Analysis (RTA) software was used to process the image analysis and base calling. Sequencing runs generated approximately 300-400 million successful reads on each lane of a flow cell, yielding 9-10 Gb per sample. With these sequencing yields, samples achieved an average of 95% of the targeted exome bases covered to a depth of 203 or greater.
Whole-exome sequencing data processing and quality control. Exome sequence data processing and analysis were performed using the standard pipelines established at Human Genome Sequencing Center (HGSC) of Baylor College of Medicine 31 . Read sequences were mapped to the human reference genome (GRCh37) by BurrowsWheeler Aligner (BWA) 32 . All BAM (Binary Alignment Map) files were processed to identify duplicates using the Picard and then recalibrated and realigned by GATK (Genome Analysis Toolkit) 33 . Quality control modules were used to compare genotypes derived from Affymetrix arrays and sequencing data to ensure concordance. Genotypes from single nucleotide polymorphism (SNP) arrays were also used to monitor for low levels of cross-contamination between samples from different individuals. The Ion Torrent sequencing data was analysed using Torrent Suite Software v3.0. Whole-exome sequencing data mutation calling and annotation. Atlas-SNP2 was used to identify somatic single-nucleotide variants in targeted exons 34 . Pindel was also applied to call small-to-medium size of insertions and deletions 35 . A minimum of 4 high-quality supporting reads and a minimum mutant allele fraction of 0.08 was required for mutation calling. Somatic mutations and germline variants were annotated using information from publicly available databases, including dbSNP build 135 and variants from the 1000 Genome project. The pipeline integrates ANNOVAR 36 to determine whether the observed amino acid changes have synonymous, non-synonymous, nonsense, or splice-site changing properties on the encoded proteins and SIFT 37 , PROVEAN (Protein Variation Effect Analyzer) 38 and Polyphen-2 39 algorithms to predict the functional impact of somatic point mutations. Variants were further annotated with entries from the Catalogue of Somatic Mutation version 52 (COSMIC, http://www.sanger.ac.uk/genetics/CGP/cosmic/) to determine if the mutations were detected at previously reported hotspots. Mutation validation. All somatic non-silent mutations identified and a subset of functionally interesting germline variants were selected for validation using the Ion Torrent Personal Genome Machine (PGM, Life Technologies Corporation). PCR primers were designed using standard Primer3 tool and the best primer pairs were selected using our on-house algorithm. PCR amplicons from the tumours and their matched blood samples were barcoded, pooled, sheared by enzymatic digestion, adaptor ligated, size selected, amplified and sequenced by Ion PGM system. The sequencing data was processed using Torrent Suite Software v3.0. The average read depth per base was 2,5333 and 1,9233 for the tumour and blood pools, respectively. A minimum of 50 high-quality supporting reads and a minimum mutant allele fraction of 0.05 was required to define a validated mutation. Furthermore, we chose 103 recurrent non-silent germline variants (allelic fraction $ 0.3, observed in both tumour and normal) to validate by Sanger sequencing (primer pairs provided on request). Gene selection for mutation prevalence screening. Genes were selected based on the following criteria: (1) genes with somatic mutations occurring in two or more patients; (2) genes with somatic mutation identified only in one patient but involved in KIT/RAS or AKT/mTOR pathways which were significantly mutated in IGCT patients (Supplementary Table 11) , interacts with KIT, tumour suppressor genes which lost the wild-type allele or mutated at COSMIC reported codons; (3) genes without somatic mutation but involve in KIT/RAS or AKT/mTOR pathways and with recurrent DNA copy number changes or have important contribution, with recurrent novel germline variants or reported by previous GWAS studies. In total, 23 potentially interesting genes were selected based on the results of the discovery study. Designing of AmpliSeq custom array. The coding exons of 23 selected genes were extracted using UCSC table browser (hg19) and submitted to Ion AmpliSeq Designer using pipeline version 1.2 using settings for standard DNA and an amplicon range 125-225 bp. The resulting custom design consists of a total of 916 amplicons. The average amplicon size was 195 bp. On average, 98.5% of the coding sequences of targeted genes were covered and the total length of covered bases is 182,447 bp (Supplementary Table 10 ). The primers were binned into two pools (pool 1: 461 amplicons and pool 2: 455 amplicons) to avoid amplification of undesired targets. Ion Torrent library construction. Ion Ampliseq library kit 2.0 (catalogue number 4480441, Life Technologies) consisting of Ampliseq PCR and library preparation reagents was used to prepare template DNA for sequencing. Ampliseq reactions were performed separately for pool 1 and pool 2 for each sample. Each Ampliseq reaction was set up using 10 ng of DNA as input. Thermo cycling conditions included, initial denaturation for 2 min at 99 uC followed by 16 annealing and extension cycles of 15 s at 99 uC and 4 min at 60 uC. Libraries were prepared using Beckman robotic workstations. Following the Ampliseq reaction, 2 ml of FuPa reagent was added to remove PCR adaptor regions and repair fragment ends. Ion Xpress Barcode Adapters were then ligated to each pool. The Post-ligation products were purified using Agencourt AMPure XP beads. Thermocycling conditions were initial denaturation for 2 min at 98 uC followed by 7 annealing and extension cycles of 15 s at 98 uC and 1 min at 60 uC. Agencourt XP beads were used to purify DNA RESEARCH LETTER after each reaction step. PCR products were purified using the above SPRI beads followed by quantification and size distribution using the LabChip GX electrophoresis system (PerkinElmer). Four to eight samples (8-16 libraries) were sequenced per run on Ion Torrent PGM instrument.
The library templates were prepared for sequencing using the Life Technologies Ion OneTouch v2 DL protocols and reagents. Briefly, library fragments were clonally amplified onto Ion Sphere Particles (ISPs) through emulsion PCR and then enriched for template-positive ISPs. More specifically, PGM emulsion PCR reactions used the Ion OneTouch 200 Template Kit v2 DL (Life Technologies, Part no. 4480285), and as specified in the accompanying protocol, emulsions and amplification were generated using the Ion OneTouch System (Life Technologies, Part no. 4467889). Following recovery, enrichment was completed by selectively binding the ISPs containing amplified library fragments to streptavidin coated magnetic beads, removing empty ISPs through washing steps, and denaturing the library strands to allow for collection of the template-positive ISPs. For all reactions, these steps were accomplished using the Life Technologies ES module of the Ion OneTouch System, and template-positive ISPs were quantified using the Guava Ion PGM sequencing data processing and mutation calling. The PGM sequencing data was processed using Ion Torrent Suite Software v3.0. Reads were aligned to the genome using TMAP against human reference genome build 37 (NCBI) with default parameters. Mutations were called using BAM files from the tumour and matched normal samples. Atlas-SNP 34 was run for SNP calling. The variants were further filtered to remove those supported by less than 5 sequencing reads or presented in less than 8% of aligned reads. For indels, the variant allele must be supported by at least 10 sequencing reads. In addition, it is requested that at least one variant had to be Q30 or better and had to lie in the central portion of the read. Besides, reads harbouring the variant must have been observed in both forward and reverse orientations. Filtering of germline variants. Germline variants were filtered step by step to identify the potentially interesting candidates. The detail workflow was described in Extended Data Fig. 7 . In brief, we first selected the non-silent variants including missense, nonsense, frameshift, and splice-site variants. Second, we selected the high-confidence variants that meet the following criteria: (1) variant allele fraction in tumour and normal equal to or greater than 0.20; (2) variant calling was supported by at least 4 sequencing reads for both tumour and normal samples. Third, we selected novel variants that haven't been reported in dbSNP database (dbSNP135). Then, we selected genes with COSMIC evidence, that is, genes for which mutations have been reported in COSMIC database in at least 100 samples. After that, for each gene in the above list, we calculated the fold of enrichment of the germline variants in Japanese IGCT patients by comparing its frequency to that of Japanese patients in the control cohort and performed Fisher's exact test to calculate the P values (Supplementary Table 7 ). The potentially interesting genes were then selected based on the IGCT frequency bias ($ 4) and significant P values (,0.05). Genome-wide SNP array. DNA copy number analyses were performed using the high resolution Illumina HumanOmni2.5-8 (Omni2.5) BeadChip Kit (Illumina). In brief, 200 ng genomic DNA was first denatured by NaOH. After neutralization of the sample, isothermal whole genome amplification was conducted to uniformly increase the DNA amount. The amplified DNA was enzymatically fragmented and hybridized to BeadChip for 16-24 h at 48 uC. After washing off unhybridized and non-specifically hybridized DNA fragments, allele-specific single-base extension reaction was performed to incorporate labelled nucleotides into the bead-bound primers. Following multi-layer staining to amply signals from the labelled extended primers and final washing and coating, beadchips were imaged using the Illumina iScan system. SNP calls were collected using the Illumina GenomeStudio Version 2011.1 Genotyping Module 1.9.4. For improved CNV analysis, B allele frequencies (BAF) were calculated and log 2 R ratios (LRR) were extracted after re-clustering the raw data by applying the GenomeStudio clustering algorithms. DNA copy number analysis. The BAF, LRR and X/Y intensities were exported using the Final Report tool of the Illumina GenomeStudio Version 2011.1 software and imported into the Circular Binary Segmentation (CBS) 40 and Gene Alteration Print (GAP) 30 pipelines. The allele-specific DNA copy number, ploidy and purity were analysed by GAP using default parameters (Supplementary Fig. 1 ). Recognition of GAP patterns was performed de novo. Clonality analysis. The subclone deconvolution consisted of several steps. First, the whole genomic BAF data of the tumour sample was filtered to exclude those SNPs that were identified as homozygous in the paired-normal sample to generate somatic LOH event profile ( Supplementary Fig. 2a) , and from it a mirrored BAF (mBAF, Supplementary Fig. 2b ) profile was calculated by the following rules 41 : mBAF 5 BAF, if BAF $ 0.5; 1 -BAF, if BAF , 0.5
The mBAF profile was then subjected to segmentation with CBS algorithm 40 ( Supplementary Figs 2c, d) . Next, the fraction (f) of cells that were harbouring the loss of heterozygosity (LOH) events for each LOH segment, with a segmental mBAF mean (u) and absolute ploidy (n), was calculated by the following formula (Supplementary Fig. 2e ). f~2 u{1 n 1{u ð Þz 2u{1 ð Þ Next, cell fractions were clustered to further reduce noise by assigning each cluster a centroid value, which was calculated as the weighted average of its member segments, the length of the segments being the weight. A subclone profile was then constructed (Supplementary Fig. 2f ) according to a specific biological model that the most prevalent mutations emerged earliest during the tumour evolutionary process, and less prevalent mutations occurred later in a linear heritage line. Thus if two LOH clusters, A and B, were identified at cell fraction 70% and 30% respectively, the model would conclude two tumorous subclones: a 40% ancestral subclone with only LOH events in cluster A and a 30% descendant subclone with both events in cluster A and B. The remaining 30% of total 100% fraction would then be deemed as normal tissue cells mixture in the tumour sample. Immunohistochemistry for AKT1. Four-mm-thick formalin-fixed, paraffinembedded sections were deparaffinized in xylene and rehydrated in graded ethanol. Antigen retrieval was performed by heating the sections for 20 min in microwave oven in 10 mM sodium citrate buffer (pH 6.0). Endogenous peroxidase activity was blocked by treating the sections in 3% hydrogen peroxide for 5 min Non-specific antigen binding was blocked by incubating the sections with 3% bovine serum albumin for 5 min. Sections were then incubated overnight with primary polyclonal goat anti-AKT1 (1:75 dilution; D-17, sc-7126; Santa Cruz Biotechnology, Inc.) Bound antibody was detected by incubating the sections with rabbit anti-goat HRP (1:200 dilution; Dako) for 1 h and then developed by EnVision1 System-HRP (DAB) (Dako) according to standard protocol. Sections were subsequently counterstained with Mayer's haematoxylin. Photomicrographs were obtained using 3100 and 3400 magnifications for low and high power images, respectively.
